푸제온
-
2009/07/14
-
2009/06/23
-
2009/06/19국가인권위원회(위원장 안경환)는 특허청장에게 환자 건강권 보호를 위해 AIDS치료제 푸제온과 관련한 특허발명의 ‘강제실시(특허권자의 시장독점권을 폐지하고 비특허권자에게 생산의 권한을 주는 것)’가 바람직하다는 의견을 표명했습니다. 이 의견 표명을 받아들여 강제실시가 발동되면 일부 AIDS환자들이 안정적으로 약을 공급받을 수 있는 길이 열리게 됩니다.
-
2009/03/04
-
2009/03/04
-
2009/03/04Fuzeon is an essential medicine for HIV/AIDS treatment, but since 2005 Roche has been withholding the distribution of the drug in Korea. We, PLWHA and AIDS activists around the world have been protested against Roche’s murderous policy. However, Roche’s only response was that they would not supply Fuzeon until the South Korean government accepts the unreasonably high price of Fuzeon. To solve this problem, Korea HIV/AIDS Network of Solidarity and Intellectual Property Left requested a compulsory license of Fuzeon in December 2008.
-
2009/02/02
-
2008/12/23
-
2008/12/23In 2004, La Roche, a multi-national pharmaceutical corporation, acquired the license to launch Fuzeon, an anti-retroviral product. However, South Korean people with HIV/AIDS have never seen this drug in the last 4 years. This was due to a strong ‘will’ of La Roche requesting the South Korean Government accept the price of 22 million KRW (roughly 22,000 USD) per year. The company has been withholding the distribution of the drug for the last 4 years. The exclusive right of patent protection, owned by La Roche, guarantees that the company’s murderous will is observed in South Korea.
-
2008/12/01